Skip to main content

We've saved some files called cookies on your device. These cookies are:

  • essential for the site to work
  • to help improve our website by collecting and reporting information on how you use it

We would also like to save some cookies to help tailor communications.

BETA
You're viewing an updated version of this service - your feedback will help us to improve it.

Contract Award Notice

Whole Genome Sequencing

  • First published: 05 April 2018
  • Last modified: 05 April 2018
  • Version: N/A
  •  

  • This file may not be fully accessible.

  •  

Information icon

The buyer is not using this website to administer the notice.

To record your interest or obtain additional information or documents please find instructions within the Full Notice Text. (NOTE: Contract Award Notices and Prior Information Notices do not normally require a response)

Contents

Summary

OCID:
Published by:
UK Biobank Limited (UK Biobank)
Authority ID:
AA22157
Publication date:
05 April 2018
Deadline date:
-
Notice type:
Contract Award Notice
Has documents:
No
Has SPD:
No
Has Carbon Reduction Plan:
N/A

Abstract

This procurement is being conducted under regulation 74 of the Public Contracts Regulations 2015 (as amended) as a light touch procedure, although we are voluntarily adopting a process akin to the open procedure. UK Biobank is issuing this tender to invite bids to conduct a vanguard phase of whole genome sequencing. The principal purpose of this vanguard phase is to inform and develop the protocols and processes for the whole genome sequencing of all UK Biobank’s 500 000 participants which is expected to take place (subject to confirmation of funding) in the next few years.

UK Biobank is a major national health resource, and a registered charity in its own right, with the aim of improving the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses – including cancer, heart diseases, stroke, diabetes, arthritis, osteoporosis, eye disorders, depression and forms of dementia.

UK Biobank recruited 500 000 people aged between 40-69 years in 2006-2010 from across the country to take part in this project. They have undergone measures, provided blood, urine and saliva samples for future analysis, given detailed information about themselves and agreed to have their health followed. Over many years this will build into a powerful resource to help scientists discover why some people develop particular diseases and others do not.

Full notice text

Contract award notice

Results of the procurement procedure

Section I: Contracting authority

I.1) Name and addresses

UK Biobank Ltd

1-2 Spectrum Way, Adswood

Stockport

SK3 0SA

UK

Contact person: Andrea Howard

Telephone: +44 1614755386

E-mail: tenders@ukbiobank.ac.uk

NUTS: UKD35

Internet address(es)

Main address: http://www.ukbiobank.ac.uk

Address of the buyer profile: https://www.mytenders.co.uk/search/Search_AuthProfile.aspx?ID=AA25607

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Whole Genome Sequencing

Reference number: UKBB005

II.1.2) Main CPV code

85148000

 

II.1.3) Type of contract

Services

II.1.4) Short description

UK Biobank requires a single sequencing provider that can offer Whole Genome Sequencing (WGS) services that meet the requirements outlined in the specification.

The key parameters for any bidder are as follows:

— There is up to GBP 30m funding available for the conduct of a vanguard phase of whole genome sequencing,

— The scope of the tender is for sequencing (and certain named ancillary) services only,

— The sequencing for this vanguard phase should ideally be completed by the end of 2019.

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement

Value excluding VAT: 30 000 000.00  GBP

II.2) Description

II.2.3) Place of performance

NUTS code:

UKD3

II.2.4) Description of the procurement

This procurement is being conducted under regulation 74 of the Public Contracts Regulations 2015 (as amended) as a light touch procedure, although we are voluntarily adopting a process akin to the open procedure. UK Biobank is issuing this tender to invite bids to conduct a vanguard phase of whole genome sequencing. The principal purpose of this vanguard phase is to inform and develop the protocols and processes for the whole genome sequencing of all UK Biobank’s 500 000 participants which is expected to take place (subject to confirmation of funding) in the next few years.

UK Biobank is a major national health resource, and a registered charity in its own right, with the aim of improving the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses – including cancer, heart diseases, stroke, diabetes, arthritis, osteoporosis, eye disorders, depression and forms of dementia.

UK Biobank recruited 500 000 people aged between 40-69 years in 2006-2010 from across the country to take part in this project. They have undergone measures, provided blood, urine and saliva samples for future analysis, given detailed information about themselves and agreed to have their health followed. Over many years this will build into a powerful resource to help scientists discover why some people develop particular diseases and others do not.

II.2.5) Award criteria

Quality criterion: Technical Requirements / Weighting: 65 %

Quality criterion: Scale / Weighting: 5 %

Quality criterion: Collaboration / Weighting: 20 %

Price / Weighting:  10 %

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.8) Information about Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.1) Previous publication concerning this procedure

Notice number in the OJ S:

2018/S 020-041805

Section V: Award of contract

A contract/lot is awarded: Yes

V.2 Award of contract

V.2.1) Date of conclusion of the contract

28/03/2018

V.2.2) Information about tenders

Number of tenders received: 17

Number of tenders received from SMEs: 3

Number of tenders received from tenderers from EU Member States: 2

Number of tenders received from tenderers from non-EU Member States: 11

Number of tenders received by electronic means: 17

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

Genome Research Limited

Wellcome Genome Campus, Hinxton

Cambridge

CB10 1SA

UK

Telephone: +44 7795460756

NUTS: UK

The contractor is an SME: No

V.2.4) Information on value of the contract/lot (excluding VAT)

Initial estimated total value of the contract/lot:

Total value of the contract/lot: : 27 400 000.00  GBP

V.2.5) Information about subcontracting

Section VI: Complementary information

VI.3) Additional information

(MT Ref:210989).

VI.4) Procedures for review

VI.4.1) Review body

UK Biobank Ltd

1-2 Spectrum Way, Adswood

Stockport

SK3 0SA

UK

Telephone: +44 1614755386

Internet address(es)

URL: http://www.ukbiobank.ac.uk

VI.5) Date of dispatch of this notice

03/04/2018

Coding

Commodity categories

ID Title Parent category
85148000 Medical analysis services Miscellaneous health services

Delivery locations

ID Description
100 UK - All

Alert region restrictions

The buyer has restricted the alert for this notice to suppliers based in the following regions.

ID Description
There are no alert restrictions for this notice.

About the buyer

Main contact:
tenders@ukbiobank.ac.uk
Admin contact:
N/a
Technical contact:
N/a
Other contact:
N/a

Further information

Date Details
No further information has been uploaded.

0800 222 9004

Lines are open 8:30am to 5pm Monday to Friday.

Rydym yn croesawu galwadau'n Gymraeg.

We welcome calls in Welsh.